Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

Telix Pharmaceuticals Limited (TLX) had Revenue of $516.68M for the most recently reported fiscal year, ending 2024-12-31.

Quarterly Annual

Figures for fiscal year ending 2024-12-31

Income Statement Financials
Revenue	$516.68M
Net Income	$32.93M
Cost of Goods Sold	$180.45M
Gross Profit	$336.23M
Operating Expenses	$462.50M
Operating Income	$54.18M
Non-Operating Income/Expense	$-17.20M
Pre-Tax Income	$36.98M
Normalized Pre-Tax Income	$36.98M
Income after Taxes	$32.93M
Income from Continuous Operations	$32.93M
Consolidated Net Income/Loss	$32.93M
Normalized Income after Taxes	$32.93M
EBIT	$54.18M
EBITDA	$59.47M
Weighted-Average Shares Outstanding (Basic)	331.23M
Weighted-Average Shares Outstanding (Diluted)	345.19M
Earnings per Share (EPS) (Basic)	$0.10
Earnings per Share (EPS) (Diluted)	$0.10
Balance Sheet Financials
Current Assets	$605.98M
Property, Plant, and Equipment	$29.65M
Long-Term Assets	$394.41M
Total Assets	$1.00B
Current Liabilities	$218.30M
Long-Term Debt	$369.41M
Long-Term Liabilities	$407.24M
Total Liabilities	$625.54M
Common Equity	$374.85M
Tangible Shareholders Equity	$100.33M
Shareholders Equity	$374.85M
Common Shares Outstanding	334.73M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$28.39M
Cash Flow from Investing Activities	$-89.17M
Cash Flow from Financial Activities	$421.50M
Beginning Cash	$81.30M
End Cash	$468.62M
Increase/Decrease in Cash	$387.32M
Stock-Based Compensation	$12.97M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	2.78
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.50
Debt to Equity Ratio	1.02
Gross Margin	65.08%
Operating Margin	10.49%
EBIT Margin	10.49%
EBITDA Margin	11.51%
Pre-Tax Profit Margin	7.16%
Profit Margin	6.37%
Free Cash Flow	$18.94M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.52
Inventory Turnover	7.17
Receiveable Turnover	5.62
Days Sales in Receivables	64.99
Return on Equity	8.79%
Return on Tangible Equity	32.82%
Return on Assets	3.29%
Return on Investments	4.42%
Book Value Per Share	$1.12
Free Cash Flow per Share	$0.05
Operating Cash Flow per Share	$0.08

Data from Zacks Investment Research, Inc.